Table of contents


Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in October 2019 on request of the sponsor.

On 2 August 2007, orphan designation (EU/3/07/462) was granted by the European Commission to SuppreMol GmbH, Germany, for recombinant human soluble Fc-gamma receptor II b for the treatment of idiopathic thrombocytopenic purpura.

The sponsorship was transferred to Baxalta Innovations GmbH, Austria in June 2017.

Key facts

Active substance
Recombinant human soluble Fc-gamma receptor II b
Disease / condition
Treatment of idiopathic thrombocytopenic purpura
Date of first decision
EU designation number

Sponsor's contact details

Baxalta Innovations GmbH
Industriestrasse 67
A-1221 Vienna

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating